Cargando…

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Battaglin, Francesca, Puccini, Alberto, Ahcene Djaballah, Selma, Lenz, Heinz-Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607986/ https://www.ncbi.nlm.nih.gov/pubmed/31388315 http://dx.doi.org/10.2147/CMAR.S186042

Ejemplares similares

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
por: Koukakis, Reija, et al.
Publicado: (2016)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions
por: Battaglin, Francesca, et al.
Publicado: (2018)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
por: Siena, Salvatore, et al.
Publicado: (2016)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
por: Köhne, Claus-Henning, et al.
Publicado: (2019)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

New perspectives for colorectal cancer
por: Puccini, Alberto, et al.
Publicado: (2017)

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
por: Taieb, Julien, et al.
Publicado: (2017)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
por: Kato, Takeshi, et al.
Publicado: (2021)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
por: Aparicio, Jorge, et al.
Publicado: (2022)

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
por: Kim, Tae Won, et al.
Publicado: (2016)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
por: Battaglin, Francesca, et al.
Publicado: (2018)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results
por: Terazawa, Tetsuji, et al.
Publicado: (2022)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
por: Bennett, L, et al.
Publicado: (2011)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
por: Piringer, Gudrun, et al.
Publicado: (2023)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
por: Han van Krieken, J., et al.
Publicado: (2017)

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab
por: Odom, Dawn, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_viegve38hdirrdtoac0n8u9442